Partnering and acquiring drug product candidates is an essential part of the pharmaceutical industry. While emerging companies are focused on drug discovery and early development, they often do not have the funding or experience to manage the complex, expensive, and time consuming path to regulatory approval. The go-forward path for these promising drug programs is to work with venture capital, private equity, or established pharma companies.
The process of due diligence enables understanding and quantifying the technical and commercial probabilities of success at each stage of drug development. This informs the relative risk and valuation for each investment.
Read this white paper to learn why Certara—with >200 experts in drug development, clinical pharmacology, and biosimulation—is the right strategic partner to bolster your ability to select the best investment opportunities.